Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Centocor’s ustekinumab will face FDA committee

Executive Summary

The Dermatologic and Ophthalmic Drugs Advisory Committee will meet June 17 to discuss Centocor's BLA for ustekinumab. The human monoclonal antibody, which targets interleukin-12 and IL-23, is proposed for the treatment of moderate to severe psoriasis. The Johnson & Johnson subsidiary filed the BLA in December, putting it in position to be first-in-class for the condition



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts